Residency · Residency · Nuclear Medicine
PET Myocardial Perfusion and Flow Quantification
PET Perfusion Tracers
Rb-82 (Rubidium-82)
Rb-82 is a potassium analog that enters myocytes via the Na+/K+-ATPase pump. It is produced from a Sr-82/Rb-82 generator operating in secular equilibrium (Sr-82 has a half-life of 25.5 days). Rb-82 has an ultra-short half-life of just 76 seconds, which enables rapid sequential rest and stress imaging but also means that pharmacologic stress is mandatory since the tracer decays too quickly for exercise protocols. Its high positron energy (3.15 MeV maximum) produces a longer positron range and consequently lower spatial resolution compared to F-18-based tracers. First-pass extraction is approximately 65% at rest and decreases at high flow rates. No on-site cyclotron is required, but the generator is expensive, costing approximately $25,000 to $30,000 per month and requiring monthly replacement. Rb-82 is currently the most widely used PET perfusion tracer in North America, with complete rest and stress imaging achievable within 30 minutes.
N-13 Ammonia
N-13 ammonia diffuses freely across cell membranes and is trapped intracellularly by glutamine synthetase. It is cyclotron-produced with a half-life of 10 minutes, necessitating an on-site cyclotron. Its first-pass extraction of approximately 80% and better flow-tracking characteristics make it superior to Rb-82 in terms of image quality, and its shorter positron range produces better spatial resolution. However, limited availability restricts its use. Imaging begins 3 to 5 minutes post-injection after blood pool clearance.
F-18 Flurpiridaz
F-18 flurpiridaz is a mitochondrial complex-I inhibitor with a near-ideal first-pass extraction of approximately 94%, providing nearly linear flow tracking even at high flow rates. Its F-18 half-life of 110 minutes allows cyclotron production with regional distribution and, importantly, makes exercise stress possible -- a significant advantage over Rb-82 and N-13 ammonia. The short positron range of F-18 provides higher spatial resolution. F-18 flurpiridaz is FDA-approved and is expected to improve detection of mild stenoses and balanced multivessel disease.
O-15 Water
O-15 water is a freely diffusible tracer with essentially 100% first-pass extraction, making it the gold standard for absolute myocardial blood flow quantification due to its perfectly linear relationship with flow. However, its very short half-life of 2.05 minutes requires an on-site cyclotron, and because it distributes into all tissues without selective myocardial retention, image quality is poor. Its use is primarily limited to research settings.
| Tracer | Half-Life | Production | Extraction | Positron Range | Exercise Stress | Key Advantage |
|---|---|---|---|---|---|---|
| Rb-82 | 76 sec | Sr-82/Rb-82 generator | ~65% | Long (5–7 mm) | No (pharmacologic only) | No cyclotron needed; rapid protocol |
| N-13 Ammonia | 10 min | Cyclotron | ~80% | Short (~1.5 mm) | No (pharmacologic only) | Superior image quality |
| F-18 Flurpiridaz | 110 min | Cyclotron (distributable) | ~94% | Shortest (~1 mm) | Yes | Near-ideal extraction; exercise capable |
| O-15 Water | 2.05 min | Cyclotron | ~100% | Short (~1 mm) | No | Gold standard for MBF (research) |
PET MPI Protocols
Rb-82 Protocol
The Rb-82 protocol begins with rest imaging: 40 to 60 mCi of Rb-82 is injected as an IV bolus, and list-mode acquisition begins at the time of injection to capture the dynamic tracer transit. After approximately 10 minutes (about 8 half-lives), residual activity is negligible. Pharmacologic stress is then administered (regadenoson or dipyridamole, since exercise is impractical with a 76-second half-life tracer), followed by a second 40 to 60 mCi Rb-82 bolus during peak stress. A low-dose CT for attenuation correction is acquired before rest and/or stress imaging. Both rest and stress dynamic data are captured for flow quantification. The entire protocol takes approximately 30 minutes.
N-13 Ammonia Protocol
For N-13 ammonia, 10 to 20 mCi is injected at rest, and imaging begins at 3 to 5 minutes post-injection for a 10 to 15 minute acquisition. After a 50-minute wait for decay (approximately 5 half-lives), a second dose is administered during stress. Dynamic acquisition is performed for flow quantification. Total protocol time is approximately 1 hour.
Gated PET
ECG-gated PET acquisition provides LVEF, ventricular volumes, and wall motion assessment, analogous to gated SPECT. The higher count rates achievable with PET allow 16-frame gating with better temporal resolution, and the reduced partial volume effect yields more accurate LVEF measurements compared to gated SPECT.
Absolute Myocardial Blood Flow (MBF) Quantification
Principle
Absolute MBF quantification is the defining advantage of PET over SPECT. Dynamic PET acquisition captures the complete time course of tracer transit from the blood pool to the myocardium. Kinetic modeling is applied using mathematical models that describe tracer uptake, retention, and washout. The input function -- the time-activity curve from the LV blood pool representing the arterial input -- is combined with myocardial uptake curves from each myocardial region. One-tissue or two-tissue compartment models are used depending on the tracer, and the software fits the model to the measured data to calculate absolute MBF in mL/min/g.
Coronary Flow Reserve (CFR)
Coronary flow reserve is calculated as the ratio of stress MBF to rest MBF. Normal CFR exceeds 2.0, with typical values ranging from 2.5 to 4.0. A reduced CFR indicates either epicardial coronary stenosis, microvascular disease, or both. A global CFR below 2.0 is associated with adverse cardiovascular events regardless of whether focal perfusion defects are present. Regional CFR reduction localizes to the territory of the stenotic vessel.
Normal Values
Normal rest MBF ranges from 0.6 to 1.0 mL/min/g, while normal stress MBF with pharmacologic vasodilation reaches 2.0 to 4.0 mL/min/g. Most laboratories use a CFR cutoff of 2.0, though some use values ranging from 1.5 to 2.5 depending on the tracer and patient population. Because rest MBF is influenced by the rate-pressure product (heart rate multiplied by systolic blood pressure), some laboratories normalize rest MBF for this hemodynamic variable.
Clinical Value of Flow Quantification
Flow quantification provides several unique clinical capabilities. In balanced ischemia detection, multivessel disease may produce a balanced reduction in flow across all territories without apparent relative perfusion defects on qualitative images; MBF quantification reveals the globally reduced stress MBF and CFR that qualitative analysis misses. In microvascular disease, patients with normal epicardial arteries but reduced CFR have microvascular dysfunction, which is common in diabetes, hypertension, and cardiac syndrome X. Flow quantification also provides powerful prognostic value: reduced CFR is an independent predictor of major adverse cardiac events, cardiac death, and all-cause mortality, adding incremental value beyond perfusion defect analysis alone. Finally, post-revascularization assessment with flow quantification can confirm functional improvement after PCI or CABG.
Advantages of PET Over SPECT for MPI
Image Quality
PET provides higher spatial resolution (4 to 5 mm versus 8 to 12 mm for SPECT), higher sensitivity and count rates resulting in less noise and shorter acquisition times, routine attenuation correction that virtually eliminates attenuation artifacts (particularly advantageous in obese patients), and time-of-flight capability that further improves signal-to-noise ratio in large patients.
Diagnostic Performance
PET MPI achieves a sensitivity of 90 to 95% and specificity of 85 to 90%, compared to 80 to 85% sensitivity and 70 to 80% specificity for SPECT. PET offers improved detection of multivessel disease through flow quantification, better detection of left main disease, and superior performance in obese patients due to fewer attenuation artifacts.
Absolute Flow Quantification
Absolute MBF quantification is unique to PET and is not routinely available with SPECT. It detects balanced ischemia and microvascular disease and provides incremental prognostic information beyond what relative perfusion analysis can offer.
Limitations
PET MPI has a higher cost (scanner, generator or cyclotron, radiopharmaceuticals), more limited availability (fewer PET/CT scanners than SPECT cameras), and the constraint that Rb-82 and N-13 ammonia require pharmacologic stress only. F-18 flurpiridaz may address several of these limitations by being distributable from centralized radiopharmacies and compatible with exercise stress.
Controversy: PET vs. SPECT as First-Line MPI
Arguments favoring PET as the first-line modality include its superior diagnostic accuracy across all patient populations, particular advantages in obese patients and women, flow quantification for balanced ischemia and microvascular disease, faster protocols (30 minutes for Rb-82 versus 3 to 5 hours for SPECT), and potentially lower radiation doses with stress-only protocols. Arguments supporting continued SPECT use include its much wider availability and lower cost, well-established interpretation criteria with decades of prognostic data, the narrowing quality gap as CZT cameras and CTAC improve SPECT performance, and the fact that exercise stress provides additional prognostic information not obtainable with Rb-82 PET. F-18 flurpiridaz may ultimately bridge this gap by combining PET-level image quality and flow quantification with exercise stress capability and broad distribution.
<image>A side-by-side comparison of Rb-82 PET and Tc-99m SPECT myocardial perfusion images in an obese patient. Show the SPECT images with significant attenuation artifacts (inferior wall defect, reduced overall image quality) versus the PET images with clear, artifact-free perfusion assessment due to robust attenuation correction and higher count rates. Demonstrate the superior image quality of PET in this challenging clinical scenario.</image>
<image>A dynamic PET acquisition and flow quantification diagram. Show the time-activity curves from the left ventricular blood pool (arterial input function showing a sharp peak and rapid washout) and from a normal myocardial segment (gradual uptake and plateau) and an ischemic segment (reduced uptake). Illustrate the compartmental model used to calculate MBF. Show a polar map displaying regional MBF values at rest and stress, with CFR calculation (stress MBF/rest MBF) for each territory.</image>
<image>An illustration of balanced ischemia detection with PET flow quantification. Show qualitative perfusion images that appear relatively normal (no focal defect because all territories are equally hypoperfused) alongside the quantitative MBF polar maps showing globally reduced stress MBF and CFR below 2.0 in all territories, revealing severe three-vessel disease that would be missed on qualitative perfusion analysis alone.</image>
Clinical Pearls
PET MPI has superior diagnostic accuracy compared with SPECT, with the greatest advantage in obese patients and women due to robust attenuation correction and higher count rates.
Absolute MBF quantification is the most important unique advantage of PET over SPECT. It detects balanced ischemia in multivessel disease that qualitative perfusion analysis misses, a scenario that can lead to falsely reassuring results on SPECT.
A global CFR below 2.0 is an independent predictor of adverse cardiovascular events, even in the absence of focal perfusion defects. This reflects both epicardial and microvascular disease.
The Rb-82 generator costs approximately $25,000 to $30,000 per month, requiring a sufficient patient volume -- typically more than 5 to 8 patients per day -- to be cost-effective.
Exercise stress is not possible with Rb-82 (76-second half-life) or N-13 ammonia (10-minute half-life). These agents require pharmacologic stress only, which means exercise hemodynamic and ECG data are not obtained.
F-18 flurpiridaz has near-ideal flow-tracking properties (94% extraction) and allows exercise stress. It may become the preferred PET perfusion tracer as it combines the advantages of PET imaging with the clinical benefits of exercise testing.
Rest MBF is influenced by hemodynamic conditions including heart rate and blood pressure. Some variability in rest MBF is normal and may warrant normalization for the rate-pressure product.
References
- Murthy VL, et al. Clinical quantification of myocardial blood flow using PET: joint position paper. J Nucl Med. 2018;59(2):273-293.
- Ziadi MC, et al. Impaired myocardial flow reserve on rubidium-82 PET imaging predicts adverse outcomes. J Am Coll Cardiol. 2011;58(7):740-748.
- Dilsizian V, et al. ASNC imaging guidelines/SNMMI procedure standard for PET nuclear cardiology procedures. J Nucl Cardiol. 2016;23(5):1187-1226.
- Maddahi J, et al. Phase III clinical trial of F-18 flurpiridaz PET for detection of coronary artery disease. J Nucl Med. 2023;64(7):1017-1023.
